Sign in

NCT06931184Enrolling by invitation

Self- Sampling in Cervical Cancer Routine Screening

Self-Sampling In Cervical Cancer Routine Screening (FALCON)

Source: ClinicalTrials.gov · Last updated 17 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

SELF-SAMPLING IN CERVICAL CANCER ROUTINE SCREENING (FALCON) -Study implements a self-sampling option for the non-attendees of the national cervical cancer screening program in the Wellbeing Services County of Pirkanmaa. HPV primary testing is currently preferred method for cervical cancer screening. The HPV-DNA self-sampling has been shown to have screening performance equal to that of provider-obtained samples. In 2024, those turning 30, 35, 40, 45, 50, 55, 60, or 65 had the opportunity to participate in the FALCON study if they do not respond to the first invitation to cervical cancer screening. From March 2025 also women living in Kanta-Häme, Central Finland, Päijät-Häme, and Ostrobothnia can take part to the study. The main objective of the FALCON study is to increase the current coverage of the cervical cancer screening program in the Pirkanmaa, Kanta-Häme, Central Finland, Päijät-Häme, and Ostrobothnia region and assess how acceptable self-sampling is for women.

Status (registry)
Enrolling by invitation
Study type
Interventional
Enrollment
40000 (estimated)
First submitted
21 Feb 2025
Start date
11 Jun 2024
Primary completion date
31 Dec 2025
Lead sponsor
Tampere University Hospital
NCT number
NCT06931184

What you commit to

  • Study type: Interventional
  • Planned participants: 40000
  • From 11 Jun 2024 to the primary completion date, 31 Dec 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Women who do not belong to the screening year 2024 or 2025 invitation birth cohorts.

Who the study is looking for

  • Women that do not respond to the first national cervical cancer screening invitation in 2024 and 2025 and to whom the reminder letter is sent to.
  • Birth cohorts of women who will turn in screening year: 30, 35, 40, 45, 50, 55, 60 or 65 years old.

Age in the registry: 30 years to 65 years · Sex: Female · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Tampere University Hospital and Tampere University
Coordinator of this site? Confirm its status
TampereFinlandUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.